Skip to main content

Table 2 Cytokine levels in serum of A375 melanoma-bearing mice

From: Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1

Cytokines

Non-Tumor bearing mice

Tumor-bearing mice

  

Days after tumor inoculation

  

7

11

17

 

Full treatment.. .

-

-

+

-

+

TNFα

9 ± 3

37 ± 12**

156 ± 29**

85 ± 15**++

215 ± 61**

25 ± 7**++

IFNα

7 ± 2

12 ± 6

15 ± 7*

10 ± 3

17 ± 8*

6 ± 3+

IFNγ

12 ± 3

16 ± 3

17 ± 2*

13 ± 4

25 ± 7**

8 ± 4++

IL-1α

4 ± 1

15 ± 4**

20 ± 6**

12 ± 1**+

18 ± 4**

5 ± 1++

IL-1β

3 ± 1

8 ± 2**

7 ± 2*

5 ± 0.5*

10 ± 2**

7 ± 1**

IL-2

78 ± 15

116 ± 32*

200 ± 43**

84 ± 12++

177 ± 36**

94 ± 14+

IL-6

39 ± 14

397 ± 147**

1244 ± 296**

795 ± 206**+

1063 ± 253**

52 ± 15++

IL-10

86 ± 22

111 ± 39

61 ± 13

77 ± 13

93 ± 27

72 ± 18

IL-12

3 ± 0.5

92 ± 27**

318 ± 76**

12 ± 4**++

244 ± 67**

14 ± 3**++

  1. Blood was collected from the tail vein every 6 h during the 24-h period of each indicated day. The days after tumor inoculation refer to those indicated in the scheme placed above the table 2. Full treatment refers to the combination of G3139 + VRP + ACV + PAC.PBP + DNR + X rays (as in table 2) that achieves a complete A375 melanoma regression. Data are mean values of the peak serum cytokine concentrations ± S.D (pg/ml) measured in 7-8 different animals. *P < 0.05, **P < 0.01 comparing for each condition versus non-tumor-bearing mice. +P < 0.05, ++P < 0.01 comparing tumor-bearing mice receiving the full treatment (+) versus tumor-bearing mice treated with physiologic saline (-).
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us